Targets › HMGCR
38 programs from 37 companies in 79 trials: 35 Phase 2, 21 Phase 4, 16 Phase 3, 7 Phase 1; Oncology, Cardiovascular, Neurology; next expected readout Nov 2026.
Catalyzes the conversion of (3S)-hydroxy-3-methylglutaryl-CoA (HMG-CoA) to mevalonic acid, the rate-limiting step in the synthesis of cholesterol and other isoprenoids, thus plays a critical role in cellular cholesterol homeostasis. HMGCR is the main target of statins, a class of cholesterol-lowering drugs. (UniProt, P04035)
Open in Phaseline: the race on HMGCR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| JW Pharmaceutical | Pitavastatin HMG-CoA reductase inhibitor | HMGCR | Phase 4 | Hypercholesterolemia; Dyslipidemias; ASCVD; Primary Prevention … | Nov 2026 |
| NYU Langone Health | Atorvastatin Calcium HMG-CoA reductase inhibitor | HMGCR | Phase 4 | Type 1 Diabetes | Jul 2027 |
| General Hospital of Shenyang Military Region | Atorvastatin Calcium HMG-CoA reductase inhibitor | HMGCR | Phase 4 | Stroke, Ischemic | Nov 2027 |
| Jung-min Ahn | High-intensity statin HMG-CoA reductase inhibitor | HMGCR | Phase 4 | Cardiovascular Diseases | Mar 2035 |
| University of Colorado, Denver | Pravastatin HMG-CoA reductase inhibitor | HMGCR | Phase 4 | ADPKD | – |
| Third Military Medical University | Simvastatin HMG-CoA reductase inhibitor | HMGCR | Phase 4 | Primary Aldosteronism | – |
| Sherief Abd-Elsalam | Statins HMG-CoA reductase inhibitor | HMGCR | Phase 3 | Rheumatoid Arthritis | Dec 2026 |
| VA Office of Research and Development | Simvastatin HMG-CoA reductase inhibitor | HMGCR | Phase 3 | Cirrhosis | Dec 2026 |
| SWOG Cancer Research Network | Simvastatin HMG-CoA reductase inhibitor | HMGCR | Phase 3 | Bladder Carcinoma | Jan 2027 |
| Lund University | Simvastatin HMG-CoA reductase inhibitor | HMGCR | Phase 3 | Graves Ophthalmopathy | Jan 2027 |
| AstraZeneca | Rosuvastatin HMG-CoA reductase inhibitor | HMGCR | Phase 3 | Hypercholesterolaemia; Acute Coronary Syndromes; Coronary Artery Disease; Statin Therapy … | May 2027 |
| Ottawa Hospital Research Institute | Rosuvastatin Calcium HMG-CoA reductase inhibitor | HMGCR | Phase 3 | Venous Thromboembolism | Jan 2028 |
| Annika Bergquist | Simvastatin HMG-CoA reductase inhibitor | HMGCR | Phase 3 | Primary Sclerosing Cholangitis | Mar 2028 |
| Northern California Institute of Research and Education | Polycap Fixed-dose combination: aspirin (antiplatelet), simvastatin (HMG-CoA reductase inhibitor), | HMGCR, ACE | Phase 3 | Stroke | Jan 2029 |
| Universitas Indonesia | Simvastatin HMG-CoA reductase inhibitor | HMGCR | Phase 2 | Triple Negative Breast Cancer | Nov 2026 |
| Northwestern University | Atorvastatin Calcium HMG-CoA reductase inhibitor | HMGCR | Phase 2 | Colorectal Carcinoma | Nov 2026 |
| Vanderbilt University | Lovastatin HMG-CoA reductase inhibitor | HMGCR | Phase 2 | Neurofibromatosis Type 1 | Jan 2027 |
| Medical University of South Carolina | Simvastatin HMG-CoA reductase inhibitor | HMGCR | Phase 2 | Prostate Cancer | Mar 2027 |
| Anna Cruceta | Simvastatin HMG-CoA reductase inhibitor | HMGCR | Phase 2 | Liver Fibrosis | Mar 2027 |
| Obafemi Awolowo University Teaching Hospital | Atorvastatin HMG-CoA reductase inhibitor | HMGCR | Phase 2 | Pulmonary Tuberculosis; Pulmonary Tuberculosis (TB) | Mar 2027 |
| National Cancer Institute, Naples | Simvastatin HMG-CoA reductase inhibitor | HMGCR | Phase 2 | Adenocarcinoma of the Pancreas; Advanced or Metastatic Gastrooesophageal Carcinoma | Jun 2027 |
| Inova Health Care Services | Simvastatin HMG-CoA reductase inhibitor | HMGCR | Phase 2 | Glioblastoma | Sep 2027 |
| Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Pravastatin HMG-CoA reductase inhibitor | HMGCR | Phase 2 | Preeclampsia (PE) | Nov 2027 |
| Emory University | Lovastatin HMG-CoA reductase inhibitor | HMGCR | Phase 2 | Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Dec 2027 |
| The First Affiliated Hospital with Nanjing Medical University | Simvastatin HMG-CoA reductase inhibitor | HMGCR | Phase 2 | Metastatic Colorectal Cancer | Dec 2027 |
| Peter MacCallum Cancer Centre, Australia | Pravastatin HMG-CoA reductase inhibitor | HMGCR | Phase 2 | Radiation-associated Dysphagia | Oct 2028 |
| Baylor Breast Care Center | Simvastatin HMG-CoA reductase inhibitor | HMGCR | Phase 2 | Breast Cancer Stage IV | Dec 2028 |
| St. Olavs Hospital | Atorvastatin HMG-CoA reductase inhibitor | HMGCR | Phase 2 | Chronic Migraine; Episodic Migraine | Dec 2028 |
| M.D. Anderson Cancer Center | Pravastatin HMG-CoA reductase inhibitor | HMGCR | Phase 2 | Lymphedema; Fibrosis Syndrome | May 2029 |
| Institut du Cancer de Montpellier - Val d'Aurelle | Pravastatin HMG-CoA reductase inhibitor | HMGCR | Phase 2 | Breast Cancer | Jan 2031 |
| Peking University People's Hospital | Atorvastatin calcium HMG-CoA reductase inhibitor | HMGCR | Phase 2 | Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I | – |
| Peking University People's Hospital | Pravastatin HMG-CoA reductase inhibitor | HMGCR | Phase 2 | Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I | – |
| Dow University of Health Sciences | Simvastatin HMG-CoA reductase inhibitor | HMGCR | Phase 2 | Pulpal Necrosis | – |
| Danae Hamouda, MD | Simvastatin HMG-CoA reductase inhibitor | HMGCR | Phase 1 | Advanced Pancreatic Cancer | Dec 2026 |
| Children's Mercy Hospital Kansas City | Pravastatin HMG-CoA reductase inhibitor | HMGCR | Phase 1 | Fontan Circulation | May 2027 |
| Tongji Hospital | Simvastatin HMG-CoA reductase inhibitor | HMGCR | Phase 1 | Advanced Biliary Tract Carcinoma | Jan 2028 |
| Kyushu University | ULREA-PVS-NP Pitavastatin encapsulated in PLGA nanoparticles; HMG-CoA reductase inhibitor delivered via | HMGCR | Phase 1 | Retinitis Pigmentosa (RP) | Jan 2028 |
| State University of New York - Downstate Medical Center | Simvastatin HMG-CoA reductase inhibitor | HMGCR | Phase 1 | Pancreatic Cancer Metastatic | Dec 2028 |
Coronary Artery Disease (5) Hypercholesterolaemia (4) Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I (3) Pulmonary Tuberculosis (3) Pulmonary Tuberculosis (TB) (3) Episodic Migraine (2) Primary Aldosteronism (2) Stroke (2) Hypercholesterolemia (2) Primary Prevention (2) Erectile Dysfunction Due to Arterial Disease (2) Ischemic Stroke (2)
small molecule (31), mixed (3), antibody (1)
Peking University People's Hospital (2) St. Olavs Hospital (1) Institut du Cancer de Montpellier - Val d'Aurelle (1) Ottawa Hospital Research Institute (1) Third Military Medical University (1) Emory University (1) Medical University of South Carolina (1) Jung-min Ahn (1) Children's Mercy Hospital Kansas City (1) Kyushu University (1) Peter MacCallum Cancer Centre, Australia (1) Northern California Institute of Research and Education (1) University of Colorado, Denver (1) JW Pharmaceutical (1) Tongji Hospital (1) AstraZeneca (1) M.D. Anderson Cancer Center (1) Dow University of Health Sciences (1) Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (1) Sherief Abd-Elsalam (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.